OmniAb (OABI) Other financing activities (2021 - 2026)
OmniAb (OABI) posted quarterly Other financing activities of $27.9 million for Q4 2025, up 755.33% year-over-year from $3.3 million in Q4 2024, and up 9279.8% quarter-over-quarter from $297000.0 in Q2 2025.
OmniAb (OABI) Other financing activities (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Other financing activities for 5 consecutive years, with $27.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities rose 755.33% year-over-year to $27.9 million; the TTM figure through Mar 2026 stood at $28.2 million (up 1125.2% YoY), while the FY2025 annual figure was $28.2 million, up 765.8% from the prior year.
- Other financing activities advanced to $27.9 million in Q4 2025 per OABI's latest filing, from $297000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $27.9 million in Q4 2025 and bottomed at -$2.1 million in Q3 2024.
- Historically, Other financing activities has averaged $2.4 million across 5 years, with a median of $297000.0 in 2025.
- On a YoY basis, Other financing activities climbed as much as 1414.88% in 2024 and fell as far as 1234.92% in 2024.
- OmniAb's Other financing activities stood at -$1.6 million in 2021, then jumped by 138.93% to $624000.0 in 2022, then plunged by 65.54% to $215000.0 in 2023, then soared by 1414.88% to $3.3 million in 2024, then soared by 755.33% to $27.9 million in 2025.
- Business Quant data shows OABI's Other financing activities at $27.9 million in Q4 2025, $297000.0 in Q2 2025, and $44000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 346,000.00 |
| Jun 30, 2026 | 346,000.00 |
| Dec 31, 2025 | 27.86 Mn |
| Dec 31, 2025 | 27.86 Mn |
| Jun 30, 2025 | 297,000.00 |
| Jun 30, 2025 | 297,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 3.26 Mn |
| Dec 31, 2024 | 3.26 Mn |
| Sep 30, 2024 | -2.15 Mn |
| Sep 30, 2024 | -2.15 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Dec 31, 2023 | 215,000.00 |
| Dec 31, 2023 | 215,000.00 |
| Sep 30, 2023 | 189,000.00 |
| Sep 30, 2023 | 189,000.00 |